Participant flow

Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN · Source last updated 2026-06-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Durvalumab in combination with intensity modulated radiotherapy (IMRT) treatments Durvalumab: Durvalumab 1500mg IV every 3 weeks for 6 cycles Intensity Modulated Radiotherapy Treatments: Total dose will be 60 Gray (Gy) at 2Gy per fractions for 30 fractions delivered Monday through Friday for 6 weeks

   id

   FG000

   title

   Open-label, Single-arm

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Withdrawal by Subject

   2. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Protocol Violation

   3. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Disease progression

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         18

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         14

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         4

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

Participants were enrolled in the study between 10/07/2019 and 05/04/2021 at three cancer centers in the United States.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice